Intellia Therapeutics stock has fallen sharply over the past few years, and the current valuation picture is mixed rather than clearly cheap or clearly expensive. After a long period of weak returns, investors are weighing whether the recent news around its gene editing trials is enough to justify where the stock now trades.

• Intellia Therapeutics shareholders have seen the stock decline about 92.2% over 5 years. This puts extra focus on whether today’s price fairly reflects the risks in its pipeline.
• The recent lifting of FDA clinical holds on the MAGNITUDE trials can support sentiment around Intellia Therapeutics’ lead programs. At the same time, the high short interest and prior safety concerns highlight that regulatory and clinical risk still sit at the center of the valuation debate.
• The company scores 3 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or an obvious overvaluation.

The issue now is whether the current price of Intellia Therapeutics stock properly reflects that mixed valuation profile and the balance between its gene editing opportunity and the risks around execution and funding.

Does Intellia Therapeutics Look Pricey on Sales?

P/S is a common way to look at a company like Intellia Therapeutics because it focuses on revenue instead of earnings, which are still negative. Intellia Therapeutics currently trades on a P/S ratio of 23.0x. That sits slightly below the peer average of 24.9x, but is more than double the broader biotech industry average of 11.0x.

The fair P/S ratio from Simply Wall St’s model is just 0.2x, which is very far below the current 23.0x. This suggests the framework is heavily penalising Intellia Therapeutics for its losses, risk profile and the quality or visibility of its revenue. Despite the recent lifting of FDA clinical holds on the MAGNITUDE trials, the stock still prices in a rich revenue multiple on this approach.

On this P/S multiple framework, Intellia Therapeutics stock appears expensive and carries a high price tag relative to the sales it currently generates.

The Intellia Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Intellia Therapeutics link the valuation puzzle above to concrete assumptions about Intellia Therapeutics' future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today. Instead of stopping at a single ratio or model output, they spell out the future that number relies on so you can track over time whether those expectations are still lining up with what actually happens. These Narratives sit on Simply Wall St's Community page and give you a structured way to connect the current share price with the underlying business story.

One of the top community narratives on Intellia Therapeutics: 59% undervalued

"Growing patient and physician enthusiasm for Intellia's lead in vivo CRISPR therapies is driving faster than expected enrollment across multiple late stage clinical trials…"

Do you think there's more to the story for Intellia Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Intellia Therapeutics, the current market multiple points to an overvalued stock on a sales basis, given the wide gap between the calculated fair P/S ratio and where the shares trade today. That tension reflects how much optimism is already embedded in expectations for its gene editing platform and potential future revenue. With the broader valuation checks still only mixed, the key question is whether Intellia Therapeutics can turn its pipeline into durable, visible revenue that investors continue to accept at a premium multiple. How that execution story unfolds will likely determine whether today’s valuation holds up or needs to reset.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.